Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Bob L who wrote (1529)	4/10/1998 1:50:00 AM
From: Maurice Winn	Respond to of 1762

Fair enough Bob, blind buying of Techniclone by IDEC wouldn't be too bright, but they are perfectly capable of sizing it up using their scientific and commercial know how. On the infection to date resulting from treatment, it seems self-evident to me that our blood contains all those B cells for a very good reason. We die without them. Not some people, but everyone [eventually - on a statistical basis]. Evolution tends to have its way. A bit like white people in sunny New Zealand are dying by the hundred from melanomas etc. Give it a few hundred years and the remaining people will all be brown. Or living indoors, venturing out only with full body armour. Medical intervention helps, but can't save all - hence these awful statistics of survival which all cancer sufferers have to look at and guess where they fit in. So no B-cells must mean serious risk of mortal infection. Especially with expected mortality from tuberculosis to rise over the next few years and infection rates to rise dramatically. 10 years for Oncolym Phase III? Have you joined the bulls? It's been 16 years already and 25 since monoclonal antibodies were proposed. As you say, until the big numbers come in from treatment of lots of people, the risk due to no B-cells compared with the risk from no Rituxan or other treatment is all guesswork - of course with good medical judgement. I was glad to see Bexxar did a good job on your person of concern. Long may it continue. " One problem is it seems to take about a year to get the full study results published in medical journals." That's a long time to wait for knowledge to trundle its way through the bureaucracy if you have cancer. Fortunately, the Web can speed things up. Why wait for a doctor's jamboree? Blood On-Line is great! Plenty of publication space in the Web too. Not limited to a certain number of pages. Maurice Go on IDEC, make an offer for Techniclone. Get some more technology to add to your portfolio. Which cost $60 million to develop and you can buy the lot for only $20 million - at today's price anyway.